The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the ...

More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to ...

To delete your data from 23andMe, you need to log in to your account and then follow these steps: Navigate to the Settings ...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

The Nasdaq-100 market index holds a lot of volatile stocks. Some of its top performers seem overvalued today, while others seem to have room for further growth. The index as a whole rose 9.1% last ...

Several states have joined a lawsuit against 23andme. They say bankruptcy shouldn't allow the genetic testing company to sell ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...